Helsinn at the 31st Annual J.P. Morgan Healthcare Conference, January 8, 2013
Lugano (ots)
Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will present an overview of the Helsinn group, its products and corporate goals at the 31st Annual J.P. Morgan Healthcare Conference, San Francisco. Dr. Braglia's presentation will be shared with an audience of institutional investors, venture-capitalist companies, global industry leaders, innovative technology creators, private investors, industry executives, business development executives and private equity firms. Approximately 300 companies are expected to present at this most important healthcare investment conference. Dr. Braglia's presentation will be webcast and can be accessed for the next three months at the following direct link:
http://www.presseportal.ch/go2/jpmorgan.metameetings.com/
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical / clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn's products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory, financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com
Contact:
Paola Bonvicini
Head of Communication & Press Office
Phone: +41/91/985'21'21
E-Mail: Info-hhc@helsinn.com